Unlock instant, AI-driven research and patent intelligence for your innovation.

Compounds adopted as cMet inhibitor, preparation method and uses thereof

A compound and solvate technology, which is applied in the preparation of hydroxyl compounds, organic compounds, carboxylic acids by oxidation, etc., can solve the problems of patient intolerance and high toxicity

Active Publication Date: 2014-03-05
SHANGHAI KECHOW PHARMA
View PDF3 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, there are many anti-tumor drugs on the market, such as alkylating agent drugs, antimetabolite drugs, anti-tumor antibiotics, immunomodulators, etc., but most of the drugs are not tolerated by patients due to their high toxicity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounds adopted as cMet inhibitor, preparation method and uses thereof
  • Compounds adopted as cMet inhibitor, preparation method and uses thereof
  • Compounds adopted as cMet inhibitor, preparation method and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0328] Example 1: 3-[(2,6-dichloro-3-fluorophenyl)sulfinyl]-5-(1-(piperidin-4-yl)-1H-(pyrazol-4-yl) -1H-Pyrrolo[2,3-b]pyridine

[0329]

[0330] Step 1: Synthesis of 5-bromo-3-iodo-1H-pyrrolo[2,3-b]pyridine

[0331] Add 5-bromo-1H-pyrrolo[2,3-b]pyridine (2.0g, 10.2mmol) into 20mL acetone, stir to dissolve, then add N-iodosuccinimide (2.7g, 12.0mmol ), stirred at room temperature for 1 h. After the reaction was completed, the solvent was evaporated under reduced pressure, dissolved in ethyl acetate (20mL), then washed successively with saturated sodium thiosulfate solution (2×30mL) and saturated brine (2×30mL), and the organic phase was washed with anhydrous sodium sulfate Dry and concentrate to obtain off-white solid (2.9g, 88.0%). 1HNMR(400MHz, CDCl3)δ9.27(s,1H),8.37(d,J=2.0Hz,1H),7.93(d,J=1.6Hz,1H),7.45(d,J=2.5Hz,1H) .

[0332] Step 2: Synthesis of 5-bromo-3-iodo-1-(4-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine

[0333] Add 5-bromo-3-iodo-1H-pyrrolo[2,3-b]pyridine (2...

Embodiment 2

[0342] Example 2: 3-(2,6-dichloro-3-fluorophenylsulfoxide)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-1H- Synthesis of Pyrazolo[3,4-b]pyridine

[0343]

[0344] Step 1: Synthesis of 5-bromo-3-iodo-1H-pyrazolo[3,4-b]pyridine

[0345] Add 5-bromo-1H-pyrazolo[3,4-b]pyridine (2.0g, 10.1mmol) into 20mL N,N-dimethylformamide, stir to dissolve, then add flake potassium hydroxide (1.2 g, 21.4mmol), stirred and reacted at room temperature for 10 minutes, then added solid iodine (2.8g, 11.1mmol), stirred and reacted for 4 small experiments at room temperature, then diluted with water (30mL), extracted with ethyl acetate (3×20mL), Then it was washed successively with saturated sodium thiosulfate solution (2×30 mL) and saturated brine (2×30 mL), and the organic phase was dried over anhydrous sodium sulfate and concentrated. Then the solid was dissolved with dioxane (30 mL), potassium hydroxide (1.2 g, 21.4 mmol) was added, and the reaction was stirred at room temperature for 10 minutes...

Embodiment 3

[0356] Example 3: 3-(1-(2,6-dichloro-3-fluorophenyl)cyclopropyl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl Synthesis of )-1H-pyrazolo[3,4-b]pyridine

[0357]

[0358] Step 1: Synthesis of 2,6-dichloro-3-fluoro-phenylethanol

[0359]Add 2,4-dichlorofluorobenzene (165.0g, 1000.0mmol) into 500mL of anhydrous tetrahydrofuran, then cool down to -78°C, add n-butyl lithium (42.0mL, 2.5M, 1050.0mmol) dropwise, and -78°C The reaction was stirred for 1 hour, then ethylene oxide (44.0 g, 1000.0 mmol) was added, and the reaction was stirred for another 2 hours at -78°C. After the reaction was completed, it was quenched with saturated ammonium chloride solution, extracted with ethyl acetate (3×200mL), the organic phase was washed with water (2×100mL) and saturated brine (2×100mL), dried over anhydrous sodium sulfate, and concentrated A colorless liquid (156.7g, 75.0%) was obtained. 1HNMR (400MHz, CDCl3) δ7.25(m,1H),7.03(m,1H),3.89(m,2H),3.29(m,2H).

[0360] Step 2: Synthesis of 2,6-di...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a substituted 1H-pyrrolo[2,3-b]pyridine compound adopted as a cMet inhibitor and a substituted 1H-pyrazolo[3,4-b]pyridine compound, a preparation method of the compounds, uses of the compounds, a compound represented by a formula (I) and pharmaceutically acceptable salts, prodrugs and solvates thereof, and a preparation method of the compound represented by the formula (I), wherein X<1>, X<2>, X<3>, X<4>, W, R<2> and R1<a-e> are defined in an instruction. The invention further discloses the preparation method of the compound represented by the formula (I) and a drug composition containing the compound represented by the formula (I).

Description

technical field [0001] The present invention relates to inhibitors of receptor tyrosine kinases, especially receptor tyrosine kinase cMet, and more particularly to inhibitors of receptor tyrosine kinases, especially receptor tyrosine kinase cMet Aminoaromatic heterocyclic compounds and pharmaceutically acceptable salts, prodrugs, solvates and pharmaceutical compositions containing these substances. Background technique [0002] The survey report of the World Health Organization shows that the global cancer situation is getting worse. In the next 20 years, the number of new patients will increase from the current 10 million to 15 million per year, and the number of deaths from cancer will also increase from 6 million to 10 million per year. Among them, primary liver cancer is a cancer that occurs in liver cells and intrahepatic bile duct epithelial cells, and is one of the most common malignant tumors in humans; lung cancer is a common malignant tumor that originates from bro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D471/04A61K31/4545A61P35/00
CPCC07C29/36C07C51/16C07C231/02C07C253/20C07D471/04C07C255/35C07C233/11C07C57/58C07C33/46
Inventor 田红旗季聪慧黄功超刘强
Owner SHANGHAI KECHOW PHARMA